Abstract: Objective To investigate the protective effect of aspartate ornithine on hepatic ischemic reperfusion injury in patients with primary liver cancer （PLC）. Methods 101 patients with PLC were recruited in our hospital between August 2015 and March 2017,and all patients with PLC received partial resection of hepatectomy. After operation,the patients were divided into control （n=50） and observation （n=51） group,receiving conventional supporting treatment and those in the observation was treated with intravenous ornithine aspartate injection. Serum malondialdehyde （MDA）,superoxide dismutase （SOD）,nitric oxide （NO） and endothelin-1（ET-1） levels were assayed. Results At the end of 7 day treatment,serum MDA level was significantly lower than in the control [（5.4±0.6） μmol/L vs.（7.3±0.9） μmol/L],serum ET-1 level was also significantly lower than in the control [（115.2±14.3） pg/L vs.（216.6±26.8） pg/L],while serum SOD level in the observation was much higher than in the control[（18.6±2.3） U/mL vs.（13.3±1.6） U/mL],and serum NO level was also significantly higher than in the control [（37.9±5.7） μmol/L vs. （22.5±3.1）μmol/L,P<0.05];serum bilirubin level in the observation group was （23.4±7.7）μmol/L,much lower than in the control[（31.3±7.8） μmol/L,P<0.05];there was no significant difference as respect to the routine blood parameters in the two groups（P>0.05）. Conclusion The application of ornithine aspartate might reduce hepatic ischemia-reperfusion injury after surgical tumor resection in patients with PLC, attributed to the protection of liver function by relieving oxygen free radical and peroxidation injury.

Key words: Hepatoma, Hepatectomy, Ornithine aspartate, Ischemia reperfusion injury, Therapy